Benzinga

Benzinga

Benzinga

mardi, août 25

BioVie Inc

BIVINASDAQ
Trade with Public
Trade with Public
$2.14
0.199.74%
À la clôture: Aug 21, 5:00 PM EST
$2.01
0.063.08%
Pré-ouverture: 5:47 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

BioVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioVie (BIVI).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOutperform# Analysts2Avg. Consensus PT$4Upside to Avg. PT+99.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 1, 2024ThinkEquityAshok KumarInitiateBuy$3
Nov 30, 2023OppenheimerJay OlsonPT CutOutperform$12→$5

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

Oppenheimer analyst Jay Olson maintains BioVie (NASDAQ:BIVI) with a Outperform and lowers the price target from $12 to $5.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

Oppenheimer analyst Jay Olson reiterates BioVie (NASDAQ:BIVI) with a Outperform and maintains $12 price target.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved